ONCOLOGY / CLINICAL EVIDENCE / MVP 0.9
Automatically check the relationship. Never prescribe treatment.
The navigator matches structured parameters against a limited editorial snapshot of primary sources. It reports an exact match, mismatch or stop reason—and makes no clinical decision.
exact FDA relationships for adults with solid tumours
match · incomplete context · blocked
doses, treatment rankings or personal prescriptions
FIRST RELEASE
Stops and precision first. Scale later.
This release covers EGFR L858R and BRAF V600E in NSCLC, MSI-H/dMMR colorectal cancer and tumour-agnostic NTRK fusion. It is not a complete biomarker list or a copy of NCCN, ESMO or Russian guidance.
These regulatory relationships apply to the United States. Russian medicine, test and indication status is not integrated in the MVP: selecting Russia stops the navigator and directs the user to clinician-led checks of the local register and guidance.
Selections are matched in browser memory against a local editorial snapshot. They are not placed in the URL, cookies, storage, analytics, the controller’s server or an external API. Do not enter or send a name, test number or report text.
The algorithm shows only an exact match, a mismatch or a stop reason. It does not compare regimens, calculate a dose or determine medical eligibility.
01 / LOGIC
Why a matching gene is not enough.
- 01
Event
An exact variant, fusion or complete signature is required—not a gene name alone.
- 02
Tumour
Morphology, stage and line must match the source; tumour-agnostic indications still have conditions.
- 03
Assay
Specimen, method, test version and result determinacy affect applicability.
- 04
Person
Contraindications, clinical status, prior therapy and patient goals remain outside the algorithm and require a clinician.
02 / STOP RULES
When uncertain, do not guess.
- VUS or unclear wording
- Unknown variant origin
- Insufficient or indeterminate specimen
- Unconfirmed method or consumer test
- Child, pregnancy or urgent situation
- Jurisdiction or indication outside the editorial set
03 / PRIMARY SOURCES
Every relationship must be verifiable.
Authorised companion diagnostics and exact test–biomarker–medicine relationships.
↗NCIWhat biomarker testing is and why it does not always identify a suitable treatment.
↗FDA / NTRKPrimary regulatory source for the tumour-agnostic NTRK relationship.
↗FDA / MSIPrimary source for first-line MSI-H/dMMR colorectal cancer.
↗Editorial snapshot reviewed 30 August 2026. Before a clinical decision, always open the current label and source for your jurisdiction.
RELATED SECTIONS